Exchange: OTC·Updated 11:53 AM EDT

RAPH Raphael Pharmaceutical Inc

$1.40
$0.00
(0.00%)
Today
Mkt Cap$28.25M
Vol228.00

About RAPH

Raphael Pharmaceutical, Inc. is a clinical-stage biotechnology company. It is focused on providing a novel cannabinoid-based research platform for the treatment of inflammatory diseases. The firm’s product candidate, HPC1, is a cannabinoid formulation developed for the treatment of rheumatoid arthritis. The company was founded in May 2007 and is headquartered in Tel Aviv, Israel.
50

Neutral Sentiment

How do you feel about RAPH?

Advertisement|Remove ads.